7 recruiting, 5 not yet recruiting, 1 active not recruiting, 1 completed. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 6, Not yet recruiting 4, Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Carboplatin (AUC 5): new trials by email Literature Review of Carboplatin (AUC 5) trials Research Report on Carboplatin (AUC 5)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 15 | 2026-08-23 | 2026-08-07 |
| Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Not yet recruiting | Tang-Du Hospital | 50 | 2026-07-10 | 2026-07-01 |
| A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors SKB518 for injection, Carboplatin (AUC 5), Bevacizumab - Advanced Gynecological Malignancies | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 280 | 2026-04-08 | 2026-05-12 |
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Cemiplimab, Fianlimab, Pemetrexed (Alimta) - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 126 | 2026-04-02 | 2026-08-11 |
| Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 82 | 2026-03-01 | 2026-02-25 |
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
| Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer Nimotuzumab, Toripalimab, Nab-paclitaxel - Head & Neck Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 10 | 2025-11-15 | 2026-01-20 |
| A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pirarubicin, Nab-paclitaxel - TNBC, Triple Negative Breast Cancer | Phase 1 | Recruiting | Xijing Hospital | 30 | 2025-11-06 | 2025-11-24 |
| A Study of Ivonescimab in First-Line ES-SCLC Ivonescimab, Cadonilimab, AK117 - Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Akeso | 180 | 2025-10-29 | 2025-11-24 |
| Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Iparomlimab/Tuvonralimab, nab-paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Recruiting | Xijing Hospital | 34 | 2025-09-25 | 2026-10-15 |
| Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors HCB101, Trastuzumab, Pertuzumab - Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | FBD Biologics Limited | 500 | 2025-03-13 | 2026-02-04 |
| A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6) - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Eli Lilly and Company | 280 | 2010-09-01 | 2019-09-13 |
Carcinoma, Non-Small-Cell Lung (3) · Pathologic Complete Response (3) · Head and Neck Neoplasms (2) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm, Residual (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Tang-Du Hospital (3) · Xijing Hospital (2) · Akeso (1) · Anhui Provincial Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Eli Lilly and Company (1) · FBD Biologics Limited (1) · German Cancer Research Center (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · Yang Hong (1)
China (10) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Poland (1) · United Kingdom (1) · United States (1)
DaQing Zhao (1) · Ning Li, MD (1) · Shujuan Liu, MD (1) · Zhao DaQing (1)
PMID 25377507, PMID 39562407, PMID 40467307, PMID 41309527, PMID 42523785
2009 (1)